Sandoz Files Biosimilar Neulasta In Europe, Praises EMA
This article was originally published in Scrip
Executive Summary
Sandoz, Novartis AG's generic drugs unit, has confirmed it has filed a market authorization application in Europe for a biosimilar version of Amgen Inc.'s Neulasta (pegfilgrastim) – the company also praised biosimilar registration processes at the EMA.
You may also be interested in...
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Sandoz announces 'complete response' letter for its pegfilgrastim 351(k) filing, suggesting it’s a tough molecule to crack at the agency.
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Sandoz announces 'complete response' letter for its pegfilgrastim 351(k) filing, suggesting it’s a tough molecule to crack at the agency.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.